Related Experiment Video

Updated: Apr 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

New developments in the treatment of castration-resistant prostate cancer

Celestia S Higano1

  • 1Presented by Celestia S. Higano, MD, Professor, Departments of Medicine and Urology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 24, 2014
PubMed

Insights

Selecting the optimal treatment for advanced prostate cancer is complex due to recent approvals. Dr. Higano discussed therapeutic options, including immunotherapy, hormonal therapy, chemotherapy, and radioisotopes, to guide clinical decisions.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Recent advancements have led to numerous new therapeutic agents for advanced prostate cancer.
  • The expanding treatment landscape presents a significant clinical challenge in selecting appropriate therapies.

Discussion:

  • Dr. Celestia Higano presented strategies for optimizing treatment selection at the NCCN 19th Annual Conference.
  • The discussion covered clinical trial data supporting various therapeutic classes.
  • Key therapeutic classes reviewed include immunotherapy, hormonal therapies, chemotherapy, and radioisotopes.

Key Insights:

  • Personalized medicine approaches are crucial for advanced prostate cancer management.
  • Understanding the efficacy and indications for each drug class is essential.
  • Evidence-based decision-making is vital for successful patient outcomes.

Outlook:

  • Continued research is expected to yield further therapeutic innovations.
  • Future strategies will likely focus on combination therapies and novel drug delivery systems.
  • Optimizing treatment sequencing will remain a critical area of focus in advanced prostate cancer care.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K